News – Page 4 – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.04.30 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

2025.01.222025.04.30 / Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...

Sound Bioventures 2024 Year in Review

2025.01.212025.01.22 / Backed by our investors and partners, Sound Bioventures has in 2024 continued to grow our impactful trans-Atlantic portfolio of life-changing biotech companies. Guided by a commitment to advance heal ...

AnaCardio press release

2025.01.092025.12.02 / AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Reports positive results from phase 1b study of AC01 in patients with heart failure and reduce ...

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172025.04.30 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192026.03.05 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122025.04.30 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

ARTHEx biotech

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

2024.10.212025.04.30 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...

Before founding Sound Bioventures, Mr. Breum was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including Sanifit (sold to Vifor Pharma), Aura Biosciences (Nasdaq: AURA), Spero Therapeutics (Nasdaq: SPRO), Nexstim (Nasdaq First North: NXTM), Biomup (Euronext: BUP).

2024.09.122024.09.12 / Prior to that, he was CEO of the venture-backed diagnostics company, ilochip A/S (technology sold to DELTA, now FORCE Technology). Before that, Mr Breum worked in the pharmaceutical industry for 15 y ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

2024.08.132025.04.30 / AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year Cambridge, MA, August 13, 2024 ...

Navigating the journey of orphan drug development

2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...